Study of Antiherpetic Efficiency of Phosphite of Acycloguanosine Ableto Over come the Barrier of Resistance to Acyclovir

Андронова, В. Л.; Jasko, Maxim V.; Kukhanova, Marina K.; Галегов, Г. А.; Skoblov, Yu. S.; Kochetkov, Sergey N.

doi:10.32607/20758251-2016-8-1-74-81

Cited by 4 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The available literature reviewed consistently supports the existence and potentiality of second-line treatments for HSV strains that are resistant to first-line treatments. We have shown that a majority of the studies reviewed have efficacy as potential managements for resistant strains of HSV [1][2][3][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][47][48][49][50][51][52][54][55][56][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122][123][124][125][127][128][129]…”

Section: Resultsmentioning

confidence: 99%

“…Within this time frame, there were two (1.46%) studies in 2015 [ 6 , 7 ], 15 (10.95%) studies in 2016 [ 1 , 3 , 8 - 20 ], 19 (13.87%) studies in 2017 [ 21 - 39 ], 27 (19.71%) studies in 2018 [ 40 - 64 ], 23 (16.79%) studies in 2019 [ 2 , 65 - 86 ], 24 (17.52%) studies in 2020 [ 87 - 110 ], and 27 (19.70%) studies in 2021 [ 111 - 137 ]. Regarding the type of studies reviewed, 121 (88.32%) studies included in vitro elements [ 2 , 3 , 6 - 12 , 14 - 20 , 23 - 26 , 28 - 42 , 44 - 47 , 49 - 56 , 58 - 64 , 66 , 68 - 72 , 74 - 77 , 79 , 80 , 82 - 87 , 89 - 118 , 120 , 122 - 133 , 135 - 139 ] and 23 (16.79%) in vivo [ 2 , 13 , 15 , 18 , 22 , 25 , 27 , 28 , 37 , 43 , 48 , 56 , 62 , 67 , 73 , 78 , 81 , 100 , …”

Section: Reviewmentioning

confidence: 99%

“…Regarding which viruses the interventions were tested on, 113 (82.48%) studies used HSV-1 [1][2][3][6][7][8][9][10][11][12][13][14][15][16]19,[21][22][23][24][25][26][27][29][30][31][33][34][35]37,38,[40][41][42][43][44][46][47][48][49]51,[53][54][55][56][60][61][62][63][64][65][67][68][69]…”

Section: Data Extractionmentioning

confidence: 99%

“…When determining the effectiveness of the proposed interventions, five (3.65%) were shown not to be effective [84,107,126,131,139], three (2.19%) were somewhat effective [21,46,53], and 128 (93.43%) were effective as potential managements for resistant strains of HSV [1][2][3][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][47][48][49][50][51][52][54][55][56][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122]…”

Section: Data Extractionmentioning

confidence: 99%

See 3 more Smart Citations

A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV

Lince¹,

DeMario²,

Yang³

et al. 2023

Cureus

View full text Add to dashboard Cite

Drug-resistant variants of herpes simplex viruses (HSV) have been reported that are not effectively treated with first-line antiviral agents. The objective of this study was to evaluate available literature on the possible efficacy of second-line treatments in HSV and the use of second-line treatments in HSV strains that are resistant to first-line treatments. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a final search was conducted in six databases on November 5, 2021 for all relevant literature using terms related to antiviral resistance, herpes, and HSV. Eligible manuscripts were required to report the presence of an existing or proposed second-line treatment for HSV-1, HSV-2, or varicella zoster virus (VZV); have full-text English-language access; and potentially reduce the rate of antiviral resistance. Following screening, 137 articles were included in qualitative synthesis. Of the included studies, articles that examined the relationship between viral resistance to first-line treatments and potential second-line treatments in HSV were included. The Cochrane risk-of-bias tool for randomized trials was used to assess risk of bias. Due to the heterogeneity of study designs, a meta-analysis of the studies was not performed. The dates in which accepted studies were published spanned from 2015-2021. In terms of sample characteristics, the majority (72.26%) of studies used Vero cells. When looking at the viruses on which the interventions were tested, the majority (84.67%) used HSV-1, with (34.31%) of these studies reporting testing on resistant HSV strains. Regarding the effectiveness of the proposed interventions, 91.97% were effective as potential managements for resistant strains of HSV. Of the papers reviewed, nectin in 2.19% of the reviews had efficacy as a second-line treatments in HSV, amenamevir in 2.19%, methanol extract in 2.19%, monoclonal antibodies in 1.46%, arbidol in 1.46%, siRNA swarms in 1.46%, Cucumis melo sulfated pectin in 1.46%, and components from Olea europeae in 1.46%. In addition to this griffithsin in 1.46% was effective, Morus alba L. in 1.46%, using nucleosides in 1.46%, botryosphaeran in 1.46%, monoterpenes in 1.46%, almond skin extracts in 1.46%, bortezomib in 1.46%, flavonoid compounds in 1.46%, andessential oils were effective in 1.46%, but not effective in 0.73%. The available literature reviewed consistently supports the existence and potentiality of second-line treatments for HSV strains that are resistant to first-line treatments. Immunocompromised patients have been noted to be the population most often affected by drug-resistant variants of HSV. Subsequently, we found that HSV infections in this patient population are challenging to manage clinically effectively. The goal of this systematic review is to provide additional information to patients on the potentiality of second-line treatment in HSV strains resistant to first-line treatments, especially those who are immunocompromised. All patients,...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Reviewmentioning

confidence: 99%

Section: Data Extractionmentioning

confidence: 99%

Section: Data Extractionmentioning

confidence: 99%

See 2 more Smart Citations

A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV

Lince¹,

DeMario²,

Yang³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…табл. 2) подавляет репродукцию ВПГ-1 в культуре клеток и защищает заражённых животных от гибели при в/б и пероральном введении (на модели генерализованной ГИ мышей); активен при использовании в виде мазевой лекарственной формы [25]. Как отмечалось выше, формирование резистентности вируса к АЦВ в подавляющем большинстве случаев связано с потерей или значительным снижением активности вирусной ТК, что, как правило, обусловливает перекрёстную резистентность вируса ко всем препаратам первого ряда.…”

Section: Introductionunclassified

MODERN ETHIOTROPIC CHEMOTHERAPY OF HERPESVIRUS INFECTIONS: ADVANCES, NEW TRENDS AND PERSPECTIVES. ALPHAHERPESVIRINAE (part I)

Андронова¹

2018

Problems of Virology

Self Cite

View full text Add to dashboard Cite

Modern therapy of infections caused by alpha-herpesviruses is based on drugs belonging to the class of modified nucleosides (acyclovir) and their metabolic progenitors - valine ester of acyclovir and famciclovir (prodrug of penciclovir). The biological activity of these compounds is determined by the similarity of their structure to natural nucleosides: modified nucleosides compete with natural nucleosides for binding to DNA-polymerase and, due to their structural features, inhibit its activity. However, the emergence of variants of viruses resistant to the antiviral drugs available in the arsenal of modern medicine necessitates the search for new compounds able of effectively inhibiting the reproduction of viruses. These compounds should be harmless to the macroorganisms, convenient to use, and overcoming the drug resistance barrier in viruses. The search for literature in international databases (PubMed, MedLine, RINC, etc.) in order to obtain information on promising developments that open new possibilities for treating herpesvirus infection and subsequent analysis of the collected data made it possible to determine not only the main trends in the search for new antiviral agents, but also to provide information on the compounds most promising for the development of anti-herpesvirus drugs.

show abstract

Transcutaneous permeation of antiviral agents

Ita

2017

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Study of Antiherpetic Efficiency of Phosphite of Acycloguanosine Ableto Over come the Barrier of Resistance to Acyclovir

Cited by 4 publications

References 35 publications

A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV

A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV

MODERN ETHIOTROPIC CHEMOTHERAPY OF HERPESVIRUS INFECTIONS: ADVANCES, NEW TRENDS AND PERSPECTIVES. ALPHAHERPESVIRINAE (part I)

Transcutaneous permeation of antiviral agents

Contact Info

Product

Resources

About